Shaped around Our Core Values of Trust, Respect, Agility, Quality and Accountability. Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. She holds a Bachelor of Applied Science from Queensland University of Technology and MBA from University of Technology Sydney. She has also completed postgraduate courses at Harvard Business School focusing on negotiation and decision making. Founded in 2017, the biotech company pioneers a new generation of complement-targeted therapies to treat immune-mediated diseases. Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Our Product offerings HAVE THE HALLMARK OF Technology-Based DIFFERENTIATION READ ABOUT OUR R&D. In 1993 she established the Transfusion Medicine Research Group at Canterbury Health Laboratories, New Zealand beginning her long association with the late Professor Hart. Kira Pharmaceuticals is a biotechnology company developing a new generation of complement-targeted therapies to treat immune-mediated diseases. HONG KONG – Kira Pharmaceuticals is riding high after completing a $46 million fundraiser and appointing Frederick Beddingfield as CEO. NameFrederick Beddingfield. But opting out of some of these cookies may affect your browsing experience. Please note that this site may contain links to third-party websites over which Kira Pharma maintains no control and therefore takes no responsibility regarding privacy considerations or content. 4560 Jinke Road, Jinchuang Plaza, Building 3, 8/F, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201210 P.R. By addressing specific market needs, Westminster Pharmaceuticals is dedicated to improving patient outcomes and reducing the cost of healthcare. Funding Events. As Vice President Immunology R&D at Janssen, his responsibilities included the clinical development of Remicade, SIMPONI and STELARA as well as other programs in rheumatology, and dermatology. Previously, he served as CEO of ToxiMet, leading the company from a development stage start-up to a fully commercial enterprise (acquired by Bio-Check UK). Kira Pharmaceuticals is a clinical stage biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. O n November 12th, Kira Pharmaceuticals emerged from stealth mode, announcing $46 million ($18 million Series A and $28 million Series B) in investments and the appointment of Frederick Beddingfield, MD, Ph.D. as Chief Executive Officer. Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences Read Press Release View All News. Kiara Health is officially the first and only customer on the African continent with a fully scaled server deployed in the AWS Cloud. Before joining ToxiMet, he worked investing in pharmaceutical and biotech stocks for one of the world’s leading hedge funds ($14B under management), and as Investment Manager for Nestle’s Corporate Venture Fund ($1.5B under management). KiRA Biotech appoints Global Pharma Business Leader as Independent Board Chair >, Immunology Company Kira Biotech launches with A$20M Series A Funding >, The Precinct, Level 2 See insights on Kira Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. After his retirement from Janssen in 2019 he has been active in continuing to be involved in bringing therapies to patients by providing scientific advice to drug development organizations. Helen also spent nineteen years in global pharmaceutical companies where she held roles of increasing responsibility managing multiple marketing teams for new and emerging portfolio products in support of clinical programming, market access strategy and market development. Kabine Close, Namugongo-Kira Road, Opp. Prior to his position at Kira Pharma, he was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. … KIRA Inc., provides facilities maintenance and construction services to federal, state, and private industries. He continued on the faculty of the University of Pennsylvania for 18 years before joining Janssen/Centocor in 2000. These cookies do not store any personal information. SECTOR. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. In this role she managed a diverse range of corporate responsibilities including development program leadership, alliance management, procurement and vendor management, business development and partnering outreach. The Company also offers base operations and renovations. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. 08 Dec 2020. by admin. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. During his tenure at Johnson & Johnson, Mr. Grissinger held various positions including Vice President Mergers and Acquisitions, Divestitures, and Head, Immunology Business Development from April 2016 to January 2018, Vice President, Corporate Development for Pharmaceuticals from January 2014 to March 2016, and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. HONG KONG – Kira Pharmaceuticals is riding high after completing a $46 million fundraiser and appointing Frederick Beddingfield as CEO. Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals. Necessary cookies are absolutely essential for the website to function properly. It serves as the local, non-exclusive manufacturing partner for a Global Top 5 pharmaceutical company and as a commercial partner for several global pharmaceutical and medical technology companies. You also have the option to opt-out of these cookies. He has over nineteen years of scientific and international management experience across the whole research, development, commercialisation, and investment process in new technologies. See insights on Kira Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. An Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs. Associate Professor Clark obtained her PhD at the Research Centre for Cancer and Transplantation, University of Melbourne, before moving to the Nuffield Department of Surgery, University of Oxford, for a postdoctoral position. Restoring, Preserving and Advancing the health of all patients, By Providing World-Class Healthcare Solutions. Comments. Kira Pharmaceuticals is a developer and researcher of antibody drugs and immunoantibody therapy. Show All. While at Johnson & Johnson, Mr. Grissinger led transactions and teams across a broad span od deal-types, geographies, and therapeutic disease areas. It serves as a the local, non-exclusive manufacturing partner for a Global Top 5 pharmaceutical company and as a commercial partner for several global pharmaceutical and medical technology companies. China ... Credit: Website Design. Siro hold a Masters in Finance from the London Business School, and a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid. GBT Pharma welcomes Kira brand Our UK sister company Precision Healthcare is proud to announce the addition of the Kira brand to the portfolio. Kiara Health (Pty) Ltd is an African pharmaceutical manufacturing and healthcare solutions company headquartered in Johannesburg, South Africa. Prior to joining IP Group, he was the Co-Founder and CEO of University of Queensland’s spin out company Molecular Warehouse, a medical diagnostics platform. We also use third-party cookies that help us analyze and understand how you use this website. Beyond Boundaries--Boundless Innovations, Boundless Connections Community Launch . Helen has extensive experience spanning 30 years of commercial, operational and program leadership roles in the Australasian pharmaceutical and biotech sectors. He has taken on the role of CEO of Kira Biotech which is an emerging Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs. Kira Pharma is located in Philadelphia, PA, United States and is part of the Drug Stores Industry. We Develop High-Quality, AFFORDABLE MEDICINES TRUSTED BY Healthcare Professionals & Patients IN 100 COUNTRIES ACROSS SIX CONTINENTS READ ABOUT OUR PRODUCTS. Kira Pharma has 4 total employees across all of its locations and generates $280,739 in sales (USD). “The $46 million comprises a series A of $18 million and a series B of $26 million, with investors Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital participating in both rounds,” Beddingfield told BioWorld. February 24, 2021 • 4:02pm EST. Sarah sought technologies for Shire in Australia, New Zealand, Singapore, Taiwan, Korea and Japan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015. Prior to joining Kira, she was CBO of Abbisko Therapeutics. Kira Pharmaceuticals has 10 employees across 2 locations and $99.50 m in total funding,. Kiara’s aspiration to deliver world-class medical solutions to all patients on the African continent resonates strongly with Imperial’s purpose to connect Africa and the world and to improve people’s lives with access to quality products and services. Kite is dedicated to curing cancer. Dan Baker received his B.A. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with … Kira Pharmaceuticals is a developer and researcher of antibody drugs and immunoantibody therapy. These cookies will be stored in your browser only with your consent. He also studied Computer Science Engineering at UNED, and speak English, German, and Spanish fluently. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with better treatments and therapy. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. 4560 Jinke Road, Jinchuang Plaza, Building 3, 8/F, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201210 P.R. ©2020 Kala Pharmaceuticals All rights reserved. Her previous roles included 5 years scouting for Shire Pharmaceuticals, a global specialty pharmaceutical company (LON: SHP). This policy describes privacy practices that apply to the Kira Pharma website. Kiara Health (Pty) Ltd is an African pharmaceutical manufacturing and healthcare solutions company headquartered in Johannesburg, South Africa. Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights Read Press Release View All News. Michael Grissinger brings decades of experience in business development, strategy, and pharmaceutical licensing leadership roles at global pharmaceutical companies. Kira Pharma General Information Description. Disclaimer: The information you have requested is not provided by Kura Oncology but by a third party and is not intended to be relied on for investment purposes. Collectively, we can all help create an inclusive world. KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES ... January 7, 2021 All news. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Pharmaceuticals is a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases. Associate Professor Clark’s research focus is on the development of therapeutic antibodies to treat haematological malignancies and other cancers. Sarah brings over 18 years of global life science business development and management experience, 13 of those years in the human healthcare industry. in Uncategorized. Developer and researcher of antibody drugs and immunoantibody therapy. This group joined the Haematology/Immunology Research Group at the University of Otago in 1997. ‘We can all choose to challenge and call out gender bias and inequality. 10 Dec 2020. by admin. KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES. Enabled by its LOGIC drug discovery platform, the company is committed to advancing first-in-class and best-in-class therapies to transform … 4560 Jinke Road, Jinchuang Plaza, Building 3, 8/F, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201210 P.R. We differentiate ourselves by offering unique Healthcare Solutions and Medical Technologies. From helping get back to a good night's … Crescendo Biologics Expands its Ongoing Collaboration with Takeda. He was also a Venture Partner at Hadean Ventures, a life sciences venture capital fund, and founder of Roundcape, a boutique advisory firm advising and co-founding startups. Sarah has a strong operational understanding of the pharmaceutical and life science industries gained through senior management roles at the Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics. Fortitude Valley, QLD 4006. Kira Pharma has 4 total employees across all of its locations and generates $280,739 in sales (USD). Frederick C. Beddingfield III is a physician-scientist, biotech entrepreneur and current CEO and director of Kira Pharmaceuticals. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with better treatments and therapy. Last week, Kira announced the company completed a $53.5 million Series B+ financing to advance its LOGIC discovery platform and a pipeline of complement-targeted therapies. Comments. Kathy He joined Kira Pharmaceuticals in July 2020 as Chief Business Officer responsible for corporate strategy and business development, where she led the close of $60M Series B+ financing. Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. “News is the first rough draft of history.” - Philip L. Graham, “The question isn’t who is going to let me; it’s who is going to stop me.” — Ayn Rand, Exxaro Resources awarded Kiara Health for its acquisition of the Novartis / Sandoz manufacturing operations. Aligned to Our Strategy to offer World-class Healthcare Solutions. Kira Pharma is located in Philadelphia, PA, United States and is part of the Drug Stores Industry. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. O n November 12th, Kira Pharmaceuticals emerged from stealth mode, announcing $46 million ($18 million Series A and $28 million Series B) in investments and the appointment of Frederick Beddingfield, MD, Ph.D. as Chief Executive Officer. We can all choose to seek out and celebrate women'sachievements. Kiara acquired the internationally GMP compliant Novartis plant, and twenty-six marketing authorisations (MAs) from Novartis’ subsidiary generic drugs manufacturer, Sandoz South Africa, contract manufacturing selected products for Sandoz SA for a four-year period. TitleCEO. Pharmaceutical manufacturer. He retired from Johnson & Johnson in January 2018 after a 22- year career. Contains corporate profile, information about products, research and development, careers and financial reports. KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES ... January 7, 2021 All news. ©2020 Kala Pharmaceuticals All rights reserved. He has multiple publications in international peer-reviewed journals. Kira Pharma respects the right to privacy of visitors to our website. ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. She is a Founder and Director of DendroCyte BioTech and Kira Biotech. Prior to Dendright, Helen was VP, Antibody Therapeutics at Implicit Bioscience where she was responsible for leading product development of an in-licensed biotech asset focused on innate immune modulation. Founded in 2017, the biotech company pioneers a new generation of complement-targeted therapies to treat immune-mediated diseases. Ansarada DealMakers SA’s Corporate Finance Magazine Annual Awards, Kiara Health is Proud to Have Won an Award at the Prestigious Ansarada DealMakers Annual Awards 2020, Kiara Health – The First and Only Company in Africa with a Fully Scaled Server Deployment in the AWS Cloud. KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES ... January 7, 2021 All news. Mr. Grissinger currently serves on the boards of Akari Therapeutics, Plc (AKTX), and Atrin Pharmaceuticals. Kira drug & pharmaceuticals active ingredients names and forms, pharmaceutical companies. Kiara Health (Pty) Ltd is an African pharmaceutical manufacturing and healthcare solutions company headquartered in Johannesburg, South Africa.